HIDATIDOSE HEPÁTICA EM PACIENTE COM HEPATITE B: RELATO DE CASO by Luis Enrique Bermejo Galan, Nayara Melo dos Santos, Domingos Sávio Matos Dantas, Roberto Carlos Cruz Carbonell, Aléxia Mahara Marques Araújo, Ana Cecília Marques de Luna, Alysson Bruno Matias Lins, Kayla Nunes Paiva, Adriana de Lima Moreira

“…Tinha biópsia hepática que evidenciava fibrose incipiente em 2010 e vinha em uso de tenofovir, mantendo carga viral do VHB< 10 UI/ml. Evoluiu com dor em quadrante superior direito do abdômen e astenia. …”
Get full text

An optimized mode of interferon intermittent therapy help improve HBsAg disappearance in chronic hepatitis B patients by Minghui Li, Minghui Li, Si Xie, Xiaoyue Bi, Fangfang Sun, Zhan Zeng, Wen Deng, Tingting Jiang, Yanjie Lin, Liu Yang, Yao Lu, Lu Zhang, Wei Yi, Yao Xie, Yao Xie

“…Patients received entecavir or tenofovir during the interval period. Hepatitis B virus (HBV) virological and serological indexes, clinical biochemical indexes, and blood routine tests were performed at the baseline and every 3 months during follow-up of initial interferon treatment. …”
Get full text

Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy by Michel Bazinet, Mark Anderson, Victor Pântea, Gheorghe Placinta, Iurie Moscalu, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Liviu Iarovoi, Valentina Smesnoi, Tatina Musteata, Alina Jucov, Ulf Dittmer, Jeff Gersch, Vera Holzmayer, Mary Kuhns, Gavin Cloherty, Andrew Vaillant

“…Therapy with nucleic acid polymers (NAPs), tenofovir disoproxil fumarate (TDF), and pegylated interferon (pegIFN) achieve high rates of HBsAg loss/seroconversion and functional cure in chronic hepatitis B virus (HBV) infection. …”
Get full text

Spanish multicentre PIBHE study: Prevalence and immunisation of chronic hepatitis B in haemodialysis patients in Spain by Rebeca García Agudo, Sami Aoufi Rabih, Guillermina Barril Cuadrado, Beatriz Proy Vega, Ángel Arias Arias, José Antonio Herruzo Gallego

“…Antiviral treatment was prescribed in 30% and suspended in 12.5%: entecavir (13.3%), lamivudine (10%), adefovir and tenofovir (6.7%), and interferon (3.3%). A total of 34.5% were candidates for renal transplantation and 6.9% had not been evaluated; 64.3% were followed up by a gastroenterologist; 27.2% of HBV(−) patients without immunisation had not been vaccinated. …”
Get full text

Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China by Zesong Sun, Jinming Ouyang, Bin Zhao, Minghui An, Lin Wang, Haibo Ding, Xiaoxu Han

“…The acquired DRM profile of 42 patients who experienced TF with tenofovir/lamivudine/efavirenz (TDF/3TC/EFV) treatment was analyzed by comparing the mutations at TF time point to those at baseline. …”
Get full text

CO-INFECÇÃO LEISHMANIOSE VISCERAL E HISTOPLASMOSE EM PACIENTE HIV POSITIVO by Francisco de Paula Rocha Aguiar Neto, Letícia Maria Fernandes de Oliveira, Pedro Allan Santos Silva, Alice Mendes Duarte, Jorge Júnior Amorim de Freitas, Hareton Teixeira Vechi, Monica Baumgardt Bay

“…Há 7 meses, o paciente havia recebido diagnóstico de HIV e iniciou Terapia Antirretroviral (Tenofovir + Lamivudina + Dolutegravir) 15 dias antes da internação. …”
Get full text

The Video intervention to Inspire Treatment Adherence for Life (VITAL Start): protocol for a multisite randomized controlled trial of a brief video-based intervention to improve an... by Maria H. Kim, Tapiwa A. Tembo, Alick Mazenga, Xiaoying Yu, Landon Myer, Rachael Sabelli, Robert Flick, Miriam Hartig, Elizabeth Wetzel, Katie Simon, Saeed Ahmed, Rose Nyirenda, Peter N. Kazembe, Mtisunge Mphande, Angella Mkandawire, Mike J. Chitani, Christine Markham, Andrea Ciaranello, Elaine J. Abrams

“…Secondary outcomes include assessments of behavioral adherence (self-reported adherence, pharmacy refill, and tenofovir diphosphate concentration), psychosocial impact, and resource utilization. …”
Get full text

Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System by Renjun Yang, Renjun Yang, Nuoya Yin, Nuoya Yin, Ying Zhao, Dandan Li, Xuanling Zhang, Xingang Li, Yang Zhang, Yang Zhang, Francesco Faiola, Francesco Faiola

“…We found a moderate or strong signal for increased risk of spontaneous abortion when comparing ETV with tenofovir disoproxil fumarate (TDF) and telbivudine (LdT), with RORs equal to 1.58 (95% CI, 1.09–2.30) and 2.13 (95% CI, 1.04–4.36), respectively. …”
Get full text

PREVALÊNCIA DO USO DE MEDICAMENTOS POTENCIALMENTE INAPROPRIADOS POR PACIENTES INFECTADOS PELO HIV EM USO DE TERAPIA ANTIRRETROVIRAL by Gabrielle Gontijo Guimarães Branco, Leonora Adami Chaves, Rosany Almeida Marques dos Anjos, Renata Fernandes Rodrigues, Renata de Oliveira Pereira, Isabela Dias Lauar, Alexandre Sampaio Moura

“…A maioria (90,11%) dos pacientes utilizavam esquemas com tenofovir (TDF) e lamivudina (3TC) associados a um terceiro medicamento, sendo, 34,9% o efavirenz (EFZ), 40,1% o dolutegravir (DTG) e 15,1% um inibidor de protease (IP) podendo ser atazanavir (ATV) ou darunavir (DRV) com booster de ritonavir (r). …”
Get full text

The right combination &ndash; treatment outcomes among HIV-positive patients initiating first-line fixed-dose antiretroviral therapy in a public sector HIV clinic in Johannesburg,... by Hirasen K, Evans D, Maskew M, Sanne IM, Shearer K, Govathson C, Malete G, Kluberg SA, Fox MP

“…We evaluated treatment outcomes among patients initiated on a FDC compared to a similar multi-pill ART regimen in Johannesburg, South Africa.Methods: We conducted a retrospective cohort study of ART-na&iuml;ve HIV-positive non-pregnant adult (&ge;18 years) patients without tuberculosis who initiated first-line ART on tenofovir and emtricitabine or lamivudine with efavirenz at Themba Lethu Clinic in Johannesburg, South Africa. …”
Get full text

Study protocol of a randomized controlled trial to assess the efficacy of the “PrEPare for Work” intervention to enhance PrEP uptake and optimize adherence for HIV prevention among... by Katie B. Biello, Philip A. Chan, Colleen D. Ndoye, Lance Nelson, Elizabeth Nelson, Vanessa Silva, Eun Kwak, Siena Napoleon, Carolina Cormack Orellana, Olly G. Richards, Evan Davis, Matthew J. Mimiaga

“…Stage 2: Those who initiate PrEP are then equally re-randomized to receive either the “PrEPare for Work Stage 2 intervention” (1-on-1 skills training, problem-solving, and motivational interviewing adherence counseling and personalized, daily text message reminders) or SOC to assess adherence (Tenofovir concentrations in hair) over 12 months of follow up. …”
Get full text

APRESENTAÇÃO ATÍPICA DE LÍQUEN SIMPLES CRÔNICO EM PACIENTE COM HIV: UM RELATO DE CASO by Pedro Vinícius Silva Felipe, Antonio Francisco de Araujo, Denise Tavares Camara do Nascimento, Ana Márcia Barreto de Carvalho, Maira Ivze Bezerra Alves

“…Iniciou-se, assim, o tratamento com Tenofovir + Lamivudina + Dolutegravir e foram solicitados demais exames complementares. …”
Get full text

Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis by Ke Zhang, Ke Zhang, Yang Zhang, Yang Zhang, Xinchao Liu, Aixin Li, Meixia Gao, Jianhua Hou, Jianhua Hou, Chunxiang Guo, Tong Zhang, Tong Zhang, Hao Wu, Hao Wu, Guanzhi Chen, Xiaojie Huang

“…For virologic suppression at 48 weeks, odds ratios (95% credible intervals) were 0.6 (0.43, 0.82) for EFV+ tenofovir disoproxil fumarate (TDF)+emtricitabine (FTC) versus DTG+ abacavir+ lamivudine (3TC) and 0.52 (0.36, 0.75) for EFV+TDF+FTC vs. …”
Get full text

Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Mul... by Chun-Yuan Lee, Chen-Hsiang Lee, Hung-Jen Tang, Hung-Chin Tsai, Chen-Hsun Yang, Yi-Pei Lin, Sheng-Fan Wang, Po-Liang Lu

“…Abstract Introduction International treatment guidelines recommend the rapid initiation of antiretroviral therapy (ART) with bictegravir (B)/emtricitabine (F)/tenofovir alafenamide (TAF) and dolutegravir (DTG)-based regimens for treatment-naïve persons living with HIV (PLWH) irrespective of their disease stage. …”
Get full text

Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa by Giovanni Villa, Adam Abdullahi, Dorcas Owusu, Colette Smith, Marilyn Azumah, Laila Sayeed, Harrison Austin, Dominic Awuah, Apostolos Beloukas, David Chadwick, Richard Phillips, Anna Maria Geretti

“…In the latter group, 50/65 (76·9%) and 55/65 (84·6%) harboured NRTI and NNRTI RAMs, respectively, and 27/65 (41·5%) had ≥1 tenofovir RAM. Among 150/164 (91·5%) viraemic patients that reattended at T1, 32/150 (21·3%) showed resuppression <40 copies/mL, comprising 1/65 (1·5%) subjects with T0 viral load ≥1000 copies/mL and 31/85 (36·5%) subjects with lower levels. …”
Get full text

Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy by Chi-Jung Wu, Gar-Yang Chau, I-Cheng Lee, Teh-Ia Huo, Chien-Wei Su, Ming-Chih Hou, Yi-Hsiang Huang

“…Methods: Consecutive 339 HBV-related HCC patients receiving surgical resection of HCC with NUCs therapy (including 256 entecavir, 36 tenofovir, and 18 lamivudine) after the surgery were retrospectively reviewed. …”
Get full text

24-h-Ambulatory Blood Pressure Monitoring in Sub-Saharan Africa: Hypertension Phenotypes and Dipping Patterns in Malawian HIV+ Patients on Antiretroviral Therapy by Philipp Kasper, Angellina Nhlema, Andrew de Forest, Hannock Tweya, Thom Chaweza, Beatrice Matanje Mwagomba, Adam M. Mula, Jane Chiwoko, Florian Neuhann, Sam Phiri, Hans-Michael Steffen

“…Methods: As part of the prospective Lighthouse-Tenofovir-Cohort-Study, we analyzed clinical, laboratory and 24-h-ambulatory blood pressure monitoring (ABPM) data of PLHIV from urban Lilongwe with treated or untreated hypertension or raised office blood pressure (OBP) during routine study-visits. …”
Get full text

O DESAFIANTE MANEJO DA COINFECÇÃO POR TUBERCULOSE, HIV E HEPATITE B, NO CONTEXTO DE DISFUNÇÃO RENAL: RELATO DE EXPERIÊNCIA by Adriane Silva Sena Lima, Julius Caesar Mendes Soares Monteiro, Brenda Lira Carvalho, Luciana Gama de Almeida, Raísa Lamara Cruz dos Santos

“…Vale ressaltar que o tratamento do vírus da hepatite B deve incluir o uso de tenofovir no esquema terapêutico, que apresenta algumas restrições nos pacientes com HIV, como resistência, efeitos colaterais e nefropatia. …”
Get full text

PROFILAXIA PRÉ-EXPOSIÇÃO AO HIV: ACESSO GARANTIDO NO MARANHÃO? by Francisco Álisson Paula de França, Tatianna Meireles Dantas de Alencar, Thiago Cherem Morelli, Rafael Santos Santana, Rodrigo Fonseca Lima

“…Introdução: A Profilaxia Pré-exposição (PrEP) é uma estratégia de prevenção que envolve o uso diário, ou no esquema “sob demanda”, de medicamentos antirretrovirais (Tenofovir/Entricitabina-TDF/FTC) por pessoas não infectadas pelo Vírus da Imunodeficiência Humana (HIV), mas, que estão em maior risco de exposição. …”
Get full text

ADESÃO EM INDIVÍDUOS COM FALHA VIROLÓGICA INICIAL EM PESSOAS VIVENDO COM HIV QUE INICIARAM A TERAPIA ANTIRRETROVIRAL – COORTE RETROSPECTIVA, BRASIL 2017-2019 (DADOS PRELIMINARES)... by Igor Francisco Chagas dos Santos, Matheus Marchesotti Dutra Ferraz, Maria das Graças Braga

“…Introdução/Objetivo: Em 2017, o dolutegravir (DTG) passou a ser recomendado com associação com lamivudina (3TC) e tenofovir (TDF) em dose fixa combinada como esquema inicial preferencial em pessoas vivendo com HIV (PVHIV) iniciando a terapia antirretroviral (TARV). …”
Get full text